Department of Physiology, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Department of Clinical Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Front Immunol. 2023 Feb 15;14:1124649. doi: 10.3389/fimmu.2023.1124649. eCollection 2023.
Sea-level residents experience altitude sickness when they hike or visit altitudes above ~2,500 m due to the hypobaric hypoxia (HH) conditions at such places. HH has been shown to drive cardiac inflammation in both ventricles by inducing maladaptive metabolic reprogramming of macrophages, which evokes aggravated proinflammatory responses, promoting myocarditis, fibrotic remodeling, arrhythmias, heart failure, and sudden deaths. The use of salidroside or altitude preconditioning (AP) before visiting high altitudes has been extensively shown to exert cardioprotective effects. Even so, both therapeutic interventions have geographical limitations and/or are inaccessible/unavailable to the majority of the population as drawbacks. Meanwhile, occlusion preconditioning (OP) has been extensively demonstrated to prevent hypoxia-induced cardiomyocyte damage by triggering endogenous cardioprotective cascades to mitigate myocardial damage. Herein, with the notion that OP can be conveniently applied anywhere, we sought to explore it as an alternative therapeutic intervention for preventing HH-induced myocarditis, remodeling, and arrhythmias.
OP intervention (6 cycles of 5 min occlusion with 200 mmHg for 5 min and 5 min reperfusion at 0 mmHg - applying to alternate hindlimb daily for 7 consecutive days) was performed, and its impact on cardiac electric activity, immunoregulation, myocardial remodeling, metabolic homeostasis, oxidative stress responses, and behavioral outcomes were assessed before and after exposure to HH in mice. In humans, before and after the application of OP intervention (6 cycles of 5 min occlusion with 130% of systolic pressure and 5 min reperfusion at 0 mmHg - applying to alternate upper limb daily for 6 consecutive days), all subjects were assessed by cardiopulmonary exercise testing (CPET).
Comparing the outcomes of OP to AP intervention, we observed that similar to the latter, OP preserved cardiac electric activity, mitigated maladaptive myocardial remodeling, induced adaptive immunomodulation and metabolic homeostasis in the heart, enhanced antioxidant defenses, and conferred resistance against HH-induce anxiety-related behavior. Additionally, OP enhanced respiratory and oxygen-carrying capacity, metabolic homeostasis, and endurance in humans.
Overall, these findings demonstrate that OP is a potent alternative therapeutic intervention for preventing hypoxia-induced myocarditis, cardiac remodeling, arrhythmias, and cardiometabolic disorders and could potentially ameliorate the progression of other inflammatory, metabolic, and oxidative stress-related diseases.
由于海平面以上~2500 米的地方存在低气压缺氧(HH)条件,海平线居民在徒步旅行或访问高海拔地区时会出现高原反应。HH 通过诱导巨噬细胞的适应性代谢重编程,导致心脏炎症,从而引发炎症反应加剧,促进心肌炎、纤维化重塑、心律失常、心力衰竭和猝死。在前往高海拔地区之前使用红景天苷或高原预处理(AP)已被广泛证明具有心脏保护作用。即便如此,这两种治疗干预都存在地理限制,并且/或者由于地理位置或无法获得,对大多数人来说并不适用。同时,闭塞预处理(OP)已被广泛证明可以通过触发内源性心脏保护级联反应来减轻心肌损伤,从而预防缺氧诱导的心肌细胞损伤。在此,鉴于 OP 可以方便地应用于任何地方,我们试图探索它作为预防 HH 引起的心肌炎、重塑和心律失常的替代治疗干预。
对小鼠进行 OP 干预(6 个周期,每个周期为 5 分钟闭塞,闭塞压力为 200mmHg,然后 5 分钟再灌注,压力为 0mmHg-每天交替闭塞后肢,连续 7 天),并在暴露于 HH 前后评估其对心脏电活动、免疫调节、心肌重塑、代谢稳态、氧化应激反应和行为结果的影响。在人类中,在应用 OP 干预(6 个周期,每个周期为 5 分钟闭塞,闭塞压力为收缩压的 130%,然后 5 分钟再灌注,压力为 0mmHg-每天交替应用于上肢,连续 6 天)前后,所有受试者均进行心肺运动测试(CPET)。
将 OP 的结果与 AP 干预进行比较,我们观察到与后者类似,OP 可以维持心脏电活动,减轻适应性心肌重塑,诱导心脏的适应性免疫调节和代谢稳态,增强抗氧化防御,并抵抗 HH 引起的焦虑相关行为。此外,OP 增强了人类的呼吸和携氧能力、代谢稳态和耐力。
总的来说,这些发现表明 OP 是预防缺氧引起的心肌炎、心脏重塑、心律失常和心脏代谢紊乱的有效替代治疗干预措施,并且可能改善其他炎症、代谢和氧化应激相关疾病的进展。